Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 10, 2025 08:00 ET | Source: Cocrystal Pharma, Inc.

Cocrystal Pharma to Present Data from Phase 1 Study of First-in-Class Norovirus Protease Inhibitor CDI-988 at the 9th International Calicivirus Conference

BOTHELL, Wash., July 10, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that its first-in-class pan-viral protease inhibitor CDI-988 has been selected for an oral...
August 15, 2022 08:00 ET | Source: Cocrystal Pharma, Inc.

Cocrystal Pharma Reports Second Quarter 2022 Financial Results and Provides Updates on its Antiviral Development Programs

Planned Phase 2a study design with orally administered CC-42344 for the treatment of pandemic and seasonal influenza AReported pharmacokinetic (PK) data from the single ascending dose portion of its...